Compounds, compositions, and methods for treating diseases
The present application is directed, in part, to compounds, and/or pharmaceutically acceptable salts or solvates thereof, and/or pharmaceutical compositions thereof, for modulating the activity of Sigma I receptor. The present application is further directed, in part, to methods for treating and/or preventing cancer using compounds disclosed herein, and/or pharmaceutically acceptable salts or solvates thereof, and/or pharmaceutical compositions thereof.
1. A compound of Formula (I),
wherein:
R 1 is selected from the group consisting of H, halo, and haloalkyl; and
R 2 is pyrimidinyl,
or a pharmaceutically acceptable salt or solvate thereof.
2. The compound of claim 1 , wherein the haloalkyl is C 1 -C 6 haloalkyl.
3. The compound of claim 1 , wherein R 1 is fluoro substituted C 1 -C 6 alkyl.
4. The compound of claim 1 , wherein R 1 is selected from the group consisting of —CF 3 , —C 2 F 5 , —CH 2 F, —CHF 2 , —CCl 3 , —CHCl 2 , and —CH 2 CF 3 .
5. The compound of claim 1 , which is selected from the group consisting of:
6. The compound of claim 1 , wherein R 2 is selected from the group consisting of
7. The compound of claim 1 , which is:
or a pharmaceutically acceptable salt or solvate thereof.
8. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof.
9. The pharmaceutical composition of claim 8 , further comprising at least one additional therapeutic agent that inhibits the ubiquitin proteasome system (UPS) or autophagic survival pathway.